Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 2/20 | 0.62 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.57 |
| ▸ | IL1RN | P18510 | 2/20 | 0.55 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.55 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.55 |
| ▸ | CTSL | P07711 | 7/20 | 0.55 |
| ▸ | CTSK | P43235 | 6/20 | 0.55 |
| ▸ | CTSS | P25774 | 1/20 | 0.55 |
| ▸ | NPY4R | P50391 | 2/20 | 0.55 |
| ▸ | NPY1R | P25929 | 1/20 | 0.55 |
| ▸ | MMP3 | P08254 | 1/20 | 0.54 |
| ▸ | CTSB | P07858 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28291922 | 0.85 | CAPN1 (0.75) | CAPN1HTRA1CTSLCTSKCTSS | |
| SCHEMBL7326037 | 0.85 | CAPN1 (0.78) | CAPN1HTRA1CTSLCTSKCTSS | |
| SCHEMBL28291921 | 0.85 | CAPN1 (0.75) | CAPN1HTRA1CTSLCTSKCTSS | |
| SCHEMBL20825246 | 0.85 | CAPN1 (0.78) | CAPN1HTRA1CTSLCTSKCTSS | |
| SCHEMBL930562 | 0.85 | IL1RN (0.57) | IL1RNERAP2ERAP1NPY4RNPY1R | |
| SCHEMBL930564 | 0.85 | IL1RN (0.57) | IL1RNERAP2ERAP1NPY4RNPY1R | |
| SCHEMBL931659 | 0.84 | CAPN1 (0.69) | CAPN1HTRA1CTSLCTSKCTSB | |
| SCHEMBL6276287 | 0.84 | CAPN1 (0.72) | CAPN1HTRA1CTSLCTSKCTSS | |
| SCHEMBL6482122 | 0.84 | CAPN1 (0.72) | CAPN1HTRA1CTSLCTSKCTSS | |
| SCHEMBL14148469 | 0.84 | CAPN1 (0.72) | CAPN1HTRA1CTSLCTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434762-B2 | Macrocyclic cysteine protease inhibitors and compositions thereof | UNIVERSITY OF CANTERBURY (NZ) | 2016-09-06 | — | — | US | disclosed |
| US-20140194362-A1 | Macrocyclic Cysteine Protease Inhibitors and Compositions Thereof | LINCOLN UNIVERSITY (NZ) | 2014-07-10 | — | — | US | disclosed |
| WO-2008048121-A2 | MACROCYCLIC CYSTEINE PROTEASE INHIBITORS AND COMPOSITIONS THEREOF | LINCOLN UNIVERSITY (NZ) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194362-A1 | Macrocyclic Cysteine Protease Inhibitors and Compositions Thereof | CAPNS1, CAPN1, CAPN9 | CAPN1 2/4885HTRA1 78/4885IL1RN 1424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.